

BIOCRYST PHARMACEUTICALS INC

Form 8-K

December 12, 2005

---

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: December 12, 2005**

**BioCryst Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-23186**  
(Commission  
File Number)

**62-1413174**  
(IRS Employer  
Identification #)

**2190 Parkway Lake Drive, Birmingham, Alabama 35244**

(Address of Principal Executive Office)

**(205) 444-4600**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

On December 12, 2005, Registrant issued a press release announcing highlights from three presentations related to the clinical development of Fodosine (forodesine hydrochloride), its lead product candidate for the treatment of certain leukemias and lymphomas, presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH). The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Neither the furnishing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to Registrant's Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at Registrant's Internet address is not part of this Current Report on Form 8-K or any other report filed by Registrant with the Securities and Exchange Commission.

**Item 9.01 Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated December 12, 2005 entitled "BioCryst Announces Presentation of Fodosine Data During the 47 <sup>th</sup> Annual Meeting and Exposition of the American Society of Hematology (ASH)".

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 12, 2005

BioCryst Pharmaceuticals, Inc.

By: /s/ Michael A. Darwin

---

Michael A. Darwin  
Chief Financial Officer and  
Chief Accounting Officer

**EXHIBIT INDEX**

<b>Item</b>	<b>Description</b>
99.1	Press release dated December 12, 2005 entitled BioCryst Announces Presentation of Fodosine Data During the 47 <sup>th</sup> Annual Meeting and Exposition of the American Society of Hematology (ASH) .